Relaxation of State Marijuana Laws to Bolster the North America Drug Screening Market

Pune, India, September, 2022/press release/- Market Research Future Published a Half-Cooked Research Report on North America Drug Screening Market Research Report.

The North America Drug Screening Market is expected to reach USD 6852.8 Million by 2030 at 9.6% CAGR during the forecast period 2022-2030, proclaims Market Research Future (MRFR) in an exhaustive research report. The North America drug screening market derives much of its growth from the growing illicit use of drugs in the region and growing awareness regarding the same. Rising prevalence of alcohol use disorder and illegal use of drugs provide impetus to the North America drug screening market. Drug screening is a standard process in North America for acquiring jobs in airlines, railways, government jobs and in places where public safety is involved which boots the growth of the market. Businesses rely on drug testing of employees as illicit drug use, or abuse can be detrimental in the workplace. With various businesses mandating drug screening in North America in an aim to increase productivity and reduce medical costs, the North America drug screening market has been able to flourish in the region. More schools in the US than ever before have mandated drug screening of students as drug abuse by students has become a common phenomenon. Drug screening of student athletes too is permissible in North America. Furthermore, the U.S. Anti-Doping Agency (USADA) has strict protocols pertaining to drug screening of athletes participating in national and international sports which bolsters the growth of the North America Drug Screening market. Misuse of prescription drugs and alcohol is most likely in older people in North America which places a significant burden on the healthcare system. Moreover, drug screening of older adults to ascertain unknown drugs they have been using for a prolonged time. Legalization of recreational marijuana and the relaxation of state marijuana laws in North America has reflected positively on the market growth. Stringent regulations mandating drug screening is also a crucial driver. However, drug screening is considered as a violation of privacy which is likely to hamper the market growth over the forecast period.

Segmentation

The North America drug screening market has been segmented based on test sample and conditions. By test sample, the market has been segmented into Urine, Hair, Blood, and Saliva. By condition, the market has been segmented into Unconsciousness, Chest Pain, Panic Attack, Drug Allergies, and Others.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of North America Drug Screening Market Research Report

Regional Analysis

The North America drug screening market covers the US and Canada. These regions have substantially high population bases who are involved in drug abuse which drives the market. North America has established stringent anti-doping regulations which support the drug screening market. Moreover, development of drug and alcohol screening devices such as organ-on-a-chip technology and rising disposable income in the region spurs the growth of the market.

Competitive Landscape

The key players operating in the North America drug screening market include Siemens Healthnieers, Quest Diagnostics, Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Roche Diagnostics, Express Diagnostics Int'l Inc., Shimadzu Corporation, Alere Toxicology, and MPD.

Industry Updates

In August 2018, Bluechiip, a technology company, extended its existing agreement with Labcon North America, to supply Labcon with chips and associated hardware necessary for drug screening. The deal is worth USD 11.6 Million and will extend up to three years.